Crescita Historical Cash Flow
| CTX Stock | CAD 0.47 0.02 4.08% |
Analysis of Crescita Therapeutics cash flow over time is an excellent tool to project Crescita Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 169.7 K or Free Cash Flow of 1.6 M as it is a great indicator of Crescita Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Crescita Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Crescita Therapeutics is a good buy for the upcoming year.
Crescita |
About Crescita Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Crescita balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Crescita's non-liquid assets can be easily converted into cash.
Crescita Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Crescita Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Crescita Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Crescita Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Crescita Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crescita Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Crescita Therapeutics' Change To Liabilities is very stable compared to the past year.
Crescita Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Crescita Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Crescita Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | (68K) | (101K) | (429K) | (393K) | (320K) | (304K) | |
| Change To Inventory | (41K) | (1.4M) | (1.8M) | (917K) | 2.2M | 2.3M | |
| Change In Cash | 5.0M | (3.0M) | (3.1M) | 1.1M | (112K) | (106.4K) | |
| Stock Based Compensation | 155K | 272K | 221K | 82K | 181K | 169.7K | |
| Free Cash Flow | 5.5M | (1.9M) | (1.2M) | 1.9M | 1.5M | 1.6M | |
| Change In Working Capital | 1.6M | (1.5M) | (3.7M) | 1.6M | 3.9M | 4.1M | |
| Begin Period Cash Flow | 9.3M | 14.3M | 11.3M | 8.2M | 9.4M | 7.9M | |
| Total Cashflows From Investing Activities | (59K) | (846K) | (290K) | (133K) | (2.0M) | (1.9M) | |
| Depreciation | 1.5M | 1.4M | 1.5M | 1.5M | 1.4M | 1.2M | |
| Other Non Cash Items | 1.9M | (773K) | 599K | 412K | (146K) | (153.3K) | |
| Capital Expenditures | 59K | 346K | 229K | 133K | 1.2M | 1.2M | |
| Total Cash From Operating Activities | 5.6M | (1.6M) | (1.0M) | 2.1M | 2.7M | 2.9M | |
| Change To Account Receivables | 1.2M | (1.0M) | (2.6M) | 3.5M | (82K) | (77.9K) | |
| Change To Operating Activities | 92K | 45K | (267K) | 273K | 314.0K | 329.6K | |
| Net Income | 37K | (1.1M) | 862K | (2.0M) | (2.8M) | (2.9M) | |
| Total Cash From Financing Activities | (476K) | (500K) | (1.8M) | (782K) | (861K) | (818.0K) | |
| End Period Cash Flow | 14.3M | 11.3M | 8.2M | 9.4M | 9.3M | 8.8M | |
| Change To Netincome | (4K) | 2.5M | (405K) | 362K | 325.8K | 309.5K | |
| Change To Liabilities | 163K | 332K | 993K | 232K | 266.8K | 280.1K | |
| Investments | (59K) | (846K) | (290K) | (133K) | (2.0M) | (1.9M) |
Pair Trading with Crescita Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crescita Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crescita Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Crescita Stock
| 0.9 | NVDA | NVIDIA CDR | PairCorr |
| 0.89 | MU | Micron Technology, | PairCorr |
| 0.88 | MSFT | Microsoft Corp CDR Earnings Call This Week | PairCorr |
| 0.84 | GOOG | Alphabet CDR | PairCorr |
| 0.83 | BA | BOEING CDR Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Crescita Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crescita Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crescita Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crescita Therapeutics to buy it.
The correlation of Crescita Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crescita Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crescita Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crescita Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Crescita Stock
The Cash Flow Statement is a financial statement that shows how changes in Crescita balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Crescita's non-liquid assets can be easily converted into cash.